Zeal Rupani - Procter Gamble Company Officer
| PGHL Stock | 5,034 307.15 5.75% |
Executive
Zeal Rupani is Company Officer of Procter Gamble Health
| Address | P&G Plaza, Mumbai, India, 400099 |
| Phone | 91 22 6866 9000 |
| Web | https://www.pghealthindia.com |
Procter Gamble Management Efficiency
The company has return on total asset (ROA) of 0.2108 % which means that it generated a profit of $0.2108 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3341 %, meaning that it generated $0.3341 on every $100 dollars invested by stockholders. Procter Gamble's management efficiency ratios could be used to measure how well Procter Gamble manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Procter Gamble's Total Current Assets are comparatively stable compared to the past year. Intangible Assets is likely to gain to about 11.6 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 2.3 B in 2025.Procter Gamble Health has accumulated 95.6 M in total debt. Debt can assist Procter Gamble until it has trouble settling it off, either with new capital or with free cash flow. So, Procter Gamble's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Procter Gamble Health sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Procter to invest in growth at high rates of return. When we think about Procter Gamble's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Govardhan Ravi | Manali Petrochemicals Limited | 40 | |
| Shivaram Narayanan | Manali Petrochemicals Limited | 55 | |
| Arvind Sharma | Garuda Construction Engineering | 39 | |
| Amin Suresh | JB Chemicals Pharmaceuticals | 56 | |
| Bhagwat Deora | JB Chemicals Pharmaceuticals | 43 | |
| Gyanesh Mathur | Manaksia Coated Metals | 67 | |
| Ashish Luhar | Chemcon Speciality Chemicals | N/A | |
| Bijayananda Mohapatra | Indian Metals Ferro | N/A | |
| Parmeshwar Bang | JB Chemicals Pharmaceuticals | 57 | |
| Manoj Dere | Zuari Agro Chemicals | N/A | |
| Savya Sachi | JB Chemicals Pharmaceuticals | 62 | |
| T Thangasagaran | Manali Petrochemicals Limited | 55 | |
| Arvind Mishra | Indian Metals Ferro | N/A | |
| Swaminathan | Manali Petrochemicals Limited | 47 | |
| Narayan Saraf | JB Chemicals Pharmaceuticals | 45 | |
| Chiragkumar Joshi | Chemcon Speciality Chemicals | N/A | |
| Sandeep Narade | Indian Metals Ferro | N/A | |
| Vikas Srivastav | Manaksia Coated Metals | N/A | |
| Rajendra Lodhi | Manaksia Coated Metals | 55 | |
| Aditya Ravi | Krebs Biochemicals and | N/A | |
| Ritesh Jain | Krebs Biochemicals and | N/A | |
Management Performance
| Return On Equity | 0.33 | ||||
| Return On Asset | 0.21 |
Procter Gamble Health Leadership Team
Elected by the shareholders, the Procter Gamble's board of directors comprises two types of representatives: Procter Gamble inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Procter. The board's role is to monitor Procter Gamble's management team and ensure that shareholders' interests are well served. Procter Gamble's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Procter Gamble's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Milind MBA, MD Director | ||
| Zeal Shah, Compliance Sec | ||
| Abhijit Roy, Director Sales | ||
| Rekha Bijoykumar, Manager Communications | ||
| Lars Atorf, Head Communications | ||
| Amit Gupta, CFO Director | ||
| Renee Connolly, Head Communications | ||
| Lokesh Chandak, Finance CFO | ||
| Sunil Punjabi, India Science | ||
| Zeal Rupani, Company Officer | ||
| Prachi Vichare, Assistant Secretary |
Procter Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Procter Gamble a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.33 | ||||
| Return On Asset | 0.21 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 86.06 B | ||||
| Shares Outstanding | 16.6 M | ||||
| Shares Owned By Insiders | 52.19 % | ||||
| Shares Owned By Institutions | 16.41 % | ||||
| Price To Book | 14.56 X | ||||
| Price To Sales | 7.46 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Procter Stock Analysis
When running Procter Gamble's price analysis, check to measure Procter Gamble's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procter Gamble is operating at the current time. Most of Procter Gamble's value examination focuses on studying past and present price action to predict the probability of Procter Gamble's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procter Gamble's price. Additionally, you may evaluate how the addition of Procter Gamble to your portfolios can decrease your overall portfolio volatility.